I'll have There now is much more here come Sunday, the 9th, but know now that Crestor is -- acoording to many Wall Street analysts -- widely expected to double its market share (~$3 billion per year in 2008, to ~$6 billion per year by 2012), as a result of the huge success of AstraZeneca's "Jupiter" study.
And it is very likely to take almost all of that share from Schering -- and Vytorin/Zetia.
More here, on Sunday -- from Louisiana.
Friday, November 7, 2008
Posted by condor at 4:24 PM